Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kramer

Showing results (221-230 of 240) with videos related to

Pageof 24
Sort By:
Frontiers in Pediatrics|April 18, 2022
Associations Between Eczema and Attention Deficit Hyperactivity Disorder Symptoms in ChildrenEvelyn Xiu Ling Loo, Delicia Shu Qin Ooi, Minyee Ong, et al.
The Lancet. Haematology|March 6, 2026
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trialLeo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, et al.
Haematologica|August 16, 2019
<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemiaSebastian Stasik, Jan M Middeke, Michael Kramer, et al.
Blood Advances|August 30, 2021
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemiaSebastian Stasik, Jan-Niklas Eckardt, Michael Kramer, et al.
Science (New York, N.Y.)|May 17, 2008
An eccentric binary millisecond pulsar in the galactic planeDavid J Champion, Scott M Ransom, Patrick Lazarus, et al.
Leukemia|January 16, 2024
Prognostic impact of CEBPA mutational subgroups in adult AMLJulia-Annabell Georgi, Sebastian Stasik, Michael Kramer, et al.
Cancers|April 30, 2021
Loss-of-Function Mutations of <i>BCOR</i> Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid LeukemiaJan-Niklas Eckardt, Sebastian Stasik, Michael Kramer, et al.
Leukemia|February 19, 2021
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trialChristoph Röllig, Hubert Serve, Richard Noppeney, et al.
Blood|July 28, 2021
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcomeFranziska Taube, Julia Annabell Georgi, Michael Kramer, et al.
Blood|June 5, 2020
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?Christoph Röllig, Michael Kramer, Christoph Schliemann, et al.
Pageof 24

Showing results (221-230 of 240) with videos related to

Sort By:
Pageof 24
Frontiers in Pediatrics|April 18, 2022
Associations Between Eczema and Attention Deficit Hyperactivity Disorder Symptoms in ChildrenEvelyn Xiu Ling Loo, Delicia Shu Qin Ooi, Minyee Ong, et al.
The Lancet. Haematology|March 6, 2026
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trialLeo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, et al.
Haematologica|August 16, 2019
<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemiaSebastian Stasik, Jan M Middeke, Michael Kramer, et al.
Blood Advances|August 30, 2021
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemiaSebastian Stasik, Jan-Niklas Eckardt, Michael Kramer, et al.
Science (New York, N.Y.)|May 17, 2008
An eccentric binary millisecond pulsar in the galactic planeDavid J Champion, Scott M Ransom, Patrick Lazarus, et al.
Leukemia|January 16, 2024
Prognostic impact of CEBPA mutational subgroups in adult AMLJulia-Annabell Georgi, Sebastian Stasik, Michael Kramer, et al.
Cancers|April 30, 2021
Loss-of-Function Mutations of <i>BCOR</i> Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid LeukemiaJan-Niklas Eckardt, Sebastian Stasik, Michael Kramer, et al.
Leukemia|February 19, 2021
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trialChristoph Röllig, Hubert Serve, Richard Noppeney, et al.
Blood|July 28, 2021
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcomeFranziska Taube, Julia Annabell Georgi, Michael Kramer, et al.
Blood|June 5, 2020
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?Christoph Röllig, Michael Kramer, Christoph Schliemann, et al.
Pageof 24